Nexus Pharmaceuticals

What Nexus Pharmaceuticals does

Nexus Pharmaceuticals is a US-based, family-owned, minority-led specialty injectable pharmaceutical manufacturer founded in 2003 and headquartered in Lincolnshire, Illinois. The company focuses on difficult-to-formulate injectable medications, with vertical integration spanning in-house R&D, manufacturing in the United States and Europe, and commercial distribution through major pharmaceutical wholesalers (Cardinal Health, McKesson, Morris & Dickson, and Cencora). Its portfolio includes FDA-approved generic injectables across antibiotics (Erythromycin Lactobionate), diagnostics (Fluorescein 10% and 25%), oxidation-reduction agents (Methylene Blue), vasodilators (Papaverine HCL), barbiturate anticonvulsants (Phenobarbital Sodium at two strengths), cardiovascular antiarrhythmics (Procainamide HCL), immunosuppressants (Tacrolimus Injection), oncology chemotherapy (Cyclophosphamide), antifibrinolytics (Tranexamic Acid), and intrathecal therapies (Baclofen Refill Kit), plus the branded product EMERPHED® (Ephedrine Sulfate). Several products are first-to-market FDA-approved specialty drugs or first AP-rated generic equivalents targeting molecules with histories of shortages.

The company generates revenue through one-time sales of FDA-approved generic and branded injectables to hospitals, hospital pharmacies, and healthcare institutions via its wholesaler network, with standard Net 30 payment terms and no publicly disclosed pricing. Its go-to-market is enterprise field sales supplemented by institutional buyer relationships through major wholesalers, and it maintains a digital presence across LinkedIn, Facebook, Instagram, YouTube, and X (Twitter) for awareness. The company's value proposition centers on ready-to-use formulations that reduce clinical labor and error potential, and on reliably addressing drug shortages for critical-need injectable medications. The company has executed multiple product launches between late 2024 and early 2026, and in June 2026 suffered a defensive setback when the Federal Circuit affirmed a permanent injunction barring marketing of its generic minocycline product in CorMedix patent litigation.

Name

Nexus Pharmaceuticals

Legal name

Nexus Pharmaceuticals, LLC

Website

https://nexuspharma.net

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Nexus Pharmaceuticals is a US-based, family-owned specialty injectable drug manufacturer developing difficult-to-formulate generic and branded injectables, serving hospitals, hospital pharmacies, and healthcare institutions through major pharmaceutical wholesalers.

Ownership category

akta.pro rank

Product category

Generic Specialty Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIABAH

Generic Finished Dosage Form (FDF) Manufacturing

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAIABAA

Small-Molecule Generics (Branded/Unbranded)

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAF

Neurology & Psychiatry (CNS) Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Generic injectable pharmaceuticals
• Specialty pharmaceutical manufacturing
• Injectable drug formulations
• FDA-approved specialty injectables
• Pharmaceutical wholesale distribution

Headquarters

HQ city

Lincolnshire

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated from manufacturing and selling FDA-approved generic injectable specialty drugs to healthcare institutions through wholesale distribution networks
2. AP-Rated Generic Equivalents: First-to-market AP-rated generic versions of branded drugs, positioning as therapeutic equivalents to established reference listed drugs

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Nexus Pharmaceuticals is a US-based pharmaceutical manufacturer that develops, produces, and commercializes difficult-to-formulate injectable medications, including FDA-approved generic specialty injectables and the branded product EMERPHED®. The company focuses on first-to-market generic equivalents and medications with histories of shortages, distributing exclusively through pharmaceutical wholesalers to hospital pharmacies and healthcare institutions across the United States.

Product overview

Nexus Pharmaceuticals is a US-based pharmaceutical manufacturer specializing in difficult-to-formulate injectable medications. The company's product portfolio consists of multiple FDA-approved generic injectable drugs across therapeutic categories including antibiotics (Erythromycin Lactobionate), diagnostic agents (Fluorescein Injection 10% and 25%), oxidation-reduction agents (Methylene Blue Injection), vasodilators (Papaverine HCL), barbiturates (Phenobarbital Sodium at two concentrations), cardiovascular antiarrhythmics (Procainamide HCL in two vial sizes), immunosuppressants (Tacrolimus Injection), and oncology chemotherapy (Cyclophosphamide Injection in 2.5 mL and 5 mL fills). The portfolio also includes the branded product EMERPHED® (Ephedrine Sulfate) for anesthesia-induced hypotension, as well as specialty products for intrathecal therapy (Baclofen Injection Refill Kit) and hemostasis (Tranexamic Acid). All products are barcoded for DSCSA standards and distributed through major pharmaceutical wholesalers. The company focuses on first-to-market opportunities and addressing drug shortage situations with high-quality injectable formulations.

Differentiator

Problem solved

Functional benefit

Brands

• EMERPHED®: Ready-to-use ephedrine sulfate injection (50 mg/10 mL) for treatment of clinically important hypotension occurring in the setting of anesthesia.

Products and services

• Erythromycin Lactobionate for Injection, USP Antibiotic injectable medication for treating infections. Supplied as 5 vials per carton, stored at controlled room temperature. Sold to hospital pharmacies and healthcare institutions through pharmaceutical wholesalers.
• Fluorescein Injection, USP 10% Diagnostic contrast agent for ophthalmic procedures at 500 mg/5 mL concentration. Supplied as 10 vials per carton to healthcare providers and eye care professionals via wholesalers.
• Fluorescein Injection, USP 25% Higher-concentration (500 mg/2 mL) diagnostic contrast agent for ophthalmic procedures, providing enhanced diagnostic flexibility in a smaller 2 mL vial format.
• Methylene Blue Injection, USP Oxidation-reduction agent for treatment of acquired methemoglobinemia. Supplied as 50 mg/10 mL (5 mg/mL) in 10 mL vials, 10 vials per carton, sold through wholesalers to hospitals.
• Papaverine HCL Injection, USP Vasodilator injectable medication at 30 mg/mL concentration, used for its smooth muscle relaxant properties. Distributed through pharmaceutical wholesalers to hospital pharmacies.
• Phenobarbital Sodium Injection, USP (130 mg/mL) Barbiturate anticonvulsant at 130 mg/mL concentration, supplied as 1 mL vials with benzyl alcohol as preservative. Sold to hospital pharmacies via wholesalers.
• Phenobarbital Sodium Injection, USP (65 mg/mL) Barbiturate anticonvulsant at 65 mg/mL concentration, providing a lower-strength alternative option for phenobarbital therapy in hospital settings.
• Procainamide HCL Injection, USP (10 mL Vial) Cardiovascular antiarrhythmic agent at 100 mg/mL concentration, supplied as 10 mL vials for cardiac rhythm management in hospitals.
• Procainamide HCL Injection, USP (2 mL Vial) Cardiovascular antiarrhythmic agent in 2 mL vial format at 100 mg/mL concentration, providing a smaller-volume option for dosing flexibility.
• Tacrolimus Injection Immunosuppressant for prevention of organ rejection in liver and kidney transplant patients, available at 5 mg/mL concentration in single-dose vials, 10 units per carton.
• Cyclophosphamide Injection (2.5 mL fill) Oncology chemotherapy agent at 200 mg/mL concentration with 500 mg per vial, supplied in ready-to-dilute multiple-dose vials. First AP-rated generic equivalent to Dr. Reddy's version.
• Cyclophosphamide Injection (5 mL fill) Oncology chemotherapy agent in 5 mL fill size (1000 mg total) at 200 mg/mL concentration, supplied as ready-to-dilute multiple-dose vials for larger dosing requirements.
• EMERPHED® (Ephedrine Sulfate) Injection Alpha- and beta-adrenergic agonist branded product indicated for treatment of clinically important hypotension occurring in the setting of anesthesia. Ready-to-use 50 mg/10 mL (5 mg/mL) injection in vial format with no compounding, diluting, or mixing required. Patent-protected.
• Baclofen Injection Refill Kit Intrathecal therapy for long-term severe spasticity management. The only vial-based refill kit option on the market, offering convenience for healthcare providers and patients.
• Tranexamic Acid Injection Antifibrinolytic agent essential for surgical bleeding control. Available in cartons of 10 bags for hospital operating room use, distributed through pharmaceutical wholesalers.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: US-focused specialty injectable generics manufacturer with a comparable hospital-channel portfolio and pipeline of difficult-to-formulate sterile injectables. Closest direct peer given similar therapeutic mix and wholesaler-mediated distribution model.
• Dr. Reddy's Laboratories: Named reference brand for Nexus's Cyclophosphamide launch; major India-based generic injectable manufacturer with US hospital-channel sales targeting the same shortage-driven therapeutic areas.
• Eugia US (Aurobindo subsidiary): Aurobindo's US specialty injectable business (Eugia) focuses on sterile injectables for the US hospital market with similar therapeutic-category overlap and pipeline of complex molecules.
• Amphastar Pharmaceuticals: Specialty injectable generics manufacturer with strong hospital channel presence and focus on shortage-prone, difficult-to-formulate injectables. Highly comparable business model, customer base, and product category mix.
• Sun Pharmaceutical Industries: Major global generic manufacturer with meaningful US specialty injectable portfolio, often targeting difficult-to-formulate molecules in oncology, anesthesia, and critical care — directly comparable to Nexus's focus.

Broad incumbents

• Teva Pharmaceutical Industries: Generic pharmaceutical leader with a substantial specialty injectable portfolio serving US hospitals and the same Big-3 wholesaler channel.
• Viatris (Mylan/Upjohn): Large diversified generics manufacturer with significant specialty injectable presence in US hospital pharmacies, overlapping in many of the same therapeutic categories (cardiovascular, anesthesia, oncology).
• Hospira / Pfizer CentreOne: Largest US injectable manufacturer historically; Pfizer's CentreOne contract manufacturing plus its specialty injectable portfolio compete head-to-head with Nexus's generic injectables in hospital channels.
• Fresenius Kabi: Global injectable pharmaceutical manufacturer with broad hospital injectables portfolio. Operates at much larger scale but competes directly in the same therapeutic categories (anesthesia, oncology, critical care) and through the same Big-3 wholesaler channel.
• Sandoz (Novartis): World's largest generic injectable manufacturer with a deep hospital-channel portfolio across antibiotics, oncology, and cardiovascular categories — directly overlapping with many of Nexus's SKUs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/NexusPharmaLLC
• YouTubeyoutube.com/c/NexusPharmaceuticalsInc
• Facebookfacebook.com/nexuspharmaceuticals
• LinkedInlinkedin.com/company/nexus-pharmaceuticals-inc-
• Instagraminstagram.com/nexuspharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexus Pharmaceuticals